IP Verse

Antiviral Therapy - EP2932970

The patent EP2932970 was granted to Viiv Healthcare on Mar 21, 2018. The application was originally filed on Jan 24, 2011 under application number EP15164931A. The patent is currently recorded with a legal status of "Revoked".

EP2932970

VIIV HEALTHCARE
Application Number
EP15164931A
Filing Date
Jan 24, 2011
Status
Revoked
Feb 14, 2024
Grant Date
Mar 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEDec 21, 2018ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSDec 19, 2018D YOUNGADMISSIBLE

Patent Citations (62) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5034394
DESCRIPTIONUS5047407
DESCRIPTIONUS5089500
DESCRIPTIONUS5519021
DESCRIPTIONUS5641889
DESCRIPTIONUS5663169
DESCRIPTIONUS5663320
DESCRIPTIONUS5693787
DESCRIPTIONUS5696254
DESCRIPTIONUS5808147
DESCRIPTIONUS5811423
DESCRIPTIONUS5840990
DESCRIPTIONUS5849911
DESCRIPTIONUS5905082
DESCRIPTIONUS5914332
DESCRIPTIONUS5917041
DESCRIPTIONUS5917042
DESCRIPTIONUS5919941
DESCRIPTIONUS5922695
DESCRIPTIONUS5935946
DESCRIPTIONUS5977089
DESCRIPTIONUS6043230
DESCRIPTIONUS6051709
DESCRIPTIONUS6069249
DESCRIPTIONUS6087383
DESCRIPTIONUS6087501
DESCRIPTIONUS6281367
DESCRIPTIONUS6294540
DESCRIPTIONUS6329522
DESCRIPTIONUS6340587
DESCRIPTIONUS6392085
DESCRIPTIONUS6436989
DESCRIPTIONUS6448403
DESCRIPTIONUS6514953
DESCRIPTIONUS6552193
DESCRIPTIONUS6555133
DESCRIPTIONUS6555687
DESCRIPTIONUS6639071
DESCRIPTIONUS6646125
DESCRIPTIONUS6870053
DESCRIPTIONUS6939964
DESCRIPTIONUS7109228
DESCRIPTIONUS7119202
DESCRIPTIONUS7534809
DESCRIPTIONWO2006116764
DESCRIPTIONWO2010068253
DESCRIPTIONWO2010068262
OPPOSITIONEP1874117
OPPOSITIONUS298589P
OPPOSITIONWO0154625
OPPOSITIONWO03016306
OPPOSITIONWO2005021001
OPPOSITIONWO2006024024
OPPOSITIONWO2006024668
OPPOSITIONWO2006116764
OPPOSITIONWO2009007441
OPPOSITIONWO2011094150
SEARCHUS2009318421
SEARCHWO2009007441
SEARCHWO2009148600
SEARCHWO2010011812
SEARCHWO2010068253

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- PHARMACEUTICAL RESEARCH, (1986), vol. 3, no. 6, page 318
DESCRIPTION- SELLESETH, D.W. ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2003), vol. 47, pages 1468 - 71
OPPOSITION- anonymous, "Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study", GSK press release, (20090700), URL: http://www.natap.org/2009/IAS/IAS_42.htm, XP 055544606
OPPOSITION- anonymous, "Antiviral Activity of S/GSK1349572, the Only Once-Daily, UnboostedIntegrase Inhibitor In Clinical Development, Evaluated In Phase 2Study", GSK press release, (20090700), URL: http://www.natap.org/2009/IAS/IAS_42.htm, XP055544606
OPPOSITION- AZIJN et al., "TMC278, a Next-Generation Nonnucleoside Reverse TranscriptaseInhibitor (NNRTI), Active against Wild-Type andNNRTI-Resistant HIV-lvt", Antimicrob Agents Chemother, (20091123), vol. 54, no. 2, pages 718 - 727, XP 055539824
OPPOSITION- "Guidelines for the use of ARVs Agents in adults and adolescents living with HIV", AIDS Info, URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
OPPOSITION- JOHNS et al., "The Discovery of S/GSK1349572: A Once Daily Next-Generation Integrase Inhibitor with a Superior Resistance Profile", 17th CROI, Conference on Retroviruses and Opportunistic Infections, San Francisco CA, (20100216), XP 055539843
OPPOSITION- JOHNS et al., "The Discovery of S/GSK1349572: A Once Daily Next-Generation Integrase Inhibitor with a Superior Resistance Profile", 17th CROI, Conference on Retroviruses and Opportunistic Infections, San Francisco CA, (20100216), XP055539843
OPPOSITION- LALEEZARI et al., "Potent Antiviral Activity of S/GSK1349572, A Next Generation integrase Inhibitor (INI), in INI-Naïve HIV-1 -infected Patients: ING111521 Protocol", IAS 2009 - 5th Conference on HIV Pathogenesis, Cape Town South Africa, (20090719), XP055280561
OPPOSITION- LALEEZARI et al., "Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naive HIV-1-Infected Patients: ING111521 Protocol", IAS 2009 - 5th Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town South Africa, (20090719), XP 055280561
OPPOSITION- POZNIAK et al., "Efficacy and safety of TMC278 in antiretroviral-naive HIV- 1 patients: week 96 results of a phase Ilb randomized trial", AIDS, (20100102), vol. 24, no. 1, pages 55 - 66, XP 055539845
OPPOSITION- UNDERWOOD et al., "S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy", IAS 2009 - 5th Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town South Africa, (20090719), URL: http://www.natap.org/2009/IAS/IAS_08.htm, XP 055544612
OPPOSITION- UNDERWOOD et al., "S/SK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy", IAS 2009 - 5th Conference on HIV Pathogenesis, (20090719), URL: http://www.natap.org/2009/IAS/IAS_08.htm, XP055544612
OPPOSITION- Scott M Hammer et al, "Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society", JAMA, (20080806), vol. 300, no. 5, pages 555 - 570, XP008134902
OPPOSITION- van Roey J. et al, "How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals", Drug Discov Today, (20080617), vol. 13, no. 13-14, pages 13 - 14, XP022797177
OPPOSITION- Goebel Frank et al, "Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1 infected subjects", AIDS, (20060822), vol. 20, no. 13, pages 1721 - 1726, XP009087366
OPPOSITION- POZNIAK et al., "Efficacy and safety of TMC278 in antiretroviral-naive HIV- 1 patients: week 96 results of a phase IIb randomized trial", AIDS, (20100102), vol. 24, no. 1, pages 55 - 66, XP055539845
OPPOSITION- AZIJN et al., "TMC278, a Next-Generation Nonnucleoside Reverse TranscriptaseInhibitor (NNRTI), Active against Wild-Type andNNRTI-Resistant HIV-lvt", Antimicrob Agents Chemother, (20091123), vol. 54, no. 2, pages 718 - 727, XP055539824
OPPOSITION- ROCKSTROH K.J. et al., "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", Eur J Med Res, (20091100), vol. 14, no. III, pages 1 - 3, XP021130215
OPPOSITION- ROCKSTROH K.J. et al., "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", Eur J Med Res, (20091124), vol. 14, no. Sup. III, pages 1 - 3, XP021130215
SEARCH- "A Phase IIb Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance", (20100115), INTERNET, URL: https://clinicaltrials.gov/archive/NCT00950859/2010_01_15, (20150804), XP002743041 [Y] 1-10 * abstract *
SEARCH- SONG I ET AL, "The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects", INTERNET CITATION, (20090912), URL: http://www.natap.org/2009/ICCAC/ICCAC_52.htm, (20130521), XP002697436 [X] 1,4-6,8-10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents